A phase II study of biweekly irinotecan (CPT-11) and 5-fluorouracil (5-FU) as first line treatment in advanced or metastatic colorectal cancer (CRC)

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

BMC Cancer ◽

10.1186/1471-2407-10-567 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 33

Author(s):

Gemma Bruera ◽

Alessandra Santomaggio ◽

Katia Cannita ◽

Paola Lanfiuti Baldi ◽

Marianna Tudini ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Annals of Oncology ◽

10.1093/annonc/mdy281.151 ◽

2018 ◽

Vol 29 ◽

pp. viii201

Author(s):

Y. Kito ◽

T. Yamada ◽

T. Matsumoto ◽

H. Yasui ◽

K. Murata ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Colorectal Cancer Patients ◽

‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’

British Journal of Cancer ◽

10.1038/sj.bjc.6602913 ◽

2005 ◽

Vol 94 (1) ◽

pp. 69-73 ◽

Cited By ~ 12

Author(s):

J Bennouna ◽

H Perrier ◽

B Paillot ◽

F Priou ◽

J H Jacob ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.4031 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 4031-4031 ◽

Cited By ~ 12

Author(s):

A. Falcone ◽

G. Masi ◽

F. Loupakis ◽

E. Vasile ◽

A. Ciarlo ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive Tumor Therapy (TTD).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e14524 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e14524-e14524

Author(s):

Alfredo Carrato ◽

Bartolomeu Massuti Sureda ◽

Manuel Benavides ◽

Carmen Guillén Ponce ◽

Esther Falco ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Tumor Therapy ◽

Single Agent ◽

Cooperative Group ◽

Line Treatment ◽

First Line ◽

A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results

Annals of Oncology ◽

10.1093/annonc/mdy149.014 ◽

2018 ◽

Vol 29 ◽

pp. v105

Author(s):

G. Chiritescu ◽

K. Dumon ◽

T. Macarulla Mercadé ◽

I. Lang ◽

C. Santos Vivas ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-003-0601-4 ◽

2003 ◽

Vol 52 (4) ◽

pp. 339-345 ◽

Cited By ~ 3

Author(s):

Juan José Reina ◽

Jorge Aparicio ◽

Javier Salvador ◽

José María Puerto Pica ◽

Antonio Rueda ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

469P Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.580 ◽

2020 ◽

Vol 31 ◽

pp. S440

Author(s):

K. Ding ◽

Y. Liu ◽

J. Chen ◽

J. Ying ◽

Q. Xu ◽

...

Keyword(s):

Colorectal Cancer ◽

Unresectable Metastatic Colorectal Cancer

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Efficacy And Safety ◽

Wild Type ◽

First Line ◽

First Line Treatment ◽

Phase II study of capecitabine and irinotecan as first-line treatment in metastatic colorectal cancer: First trial of the Brazilian Oncology Consortium (BOC-CRC 001)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3725 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3725-3725

Author(s):

C. H. Barrios ◽

F. Viola ◽

L. Camillo-Coura ◽

R. F. Silva ◽

A. Del Giglio ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽